Ewing's Sarcoma Treatments: Exatecan
Basic Information
- Exatecan is also called exatecan mesylate or DX-8951F.
- Exatecan is a topoisomerase-1 inhibitor with activity in varied solid and hematologic tumors.
- It is similar to topotecan and irinotecan.
Research Results: Ewing's Sarcoma
-
The phase 1 trial had 7 ES patients; 2/7 with stable disease. Source is research nurse of Dr. Demetri at Dana Farber in Boston
Research Results: non-Ewing's Sarcoma
- 2004 abstract discussing results of a Phase III study using exatecan
- 2003 abstract discussing a 21-day continuous iv infusion method of receiving exatecan. (San Antonio, TX)
- 2003 abstract discussing Phase 1 results using a 30-minute infusion (Oxford, UK)
Completed and Closed Clinical Trials
- Multi-center pediatric Phase 1 trial for advanced solid tumors
- Phase 2 trial underway at MD Anderson and MSK (and other places)
- European multi-center Phase 2 trial on young adult/adult advanced STS which doesn't allow Ewing's sarcoma